COVID-19 Funding Opportunities
The Office of the Vice Provost for Research (VPR) has compiled a list of funding opportunities specific to COVID-19. This list will be updated as new opportunities arise.
Application deadline: September
These clinical research grants award
ICTR Clinical Research Unit resources to investigators based on
merit and willingness to be actively monitored by the Translational
Research Evaluation Committee for study-specific milestones. Grants
are for one year with possible renewal based on study progress and achieving
BOOST awards are for junior investigators,
first-time R01 awardees, K awardees, and KL2 scholars to generate pilot
data for a larger grant submission or to supplement research funds for
the K project.
PROPEL awards are intended for established
investigators who are performing early stage clinical trials, deep phenotyping
studies, or studies that address Maryland health priorities and can
augment resources of a funded project or provide resources for small
pilot and feasibility studies.
Any Johns Hopkins University faculty member interested
in funding for a new or ongoing clinical research project is eligible
to apply. All investigators must submit an application to a Johns Hopkins
Institutional Review Board before beginning the application.
Apply by 11:59 pm, Monday, September 14.
information on the Boost and Propel Awards is available.
Internal application deadline: September 10,
The Parker B. Francis Fellowship in Pulmonary Research is intended to support the development of outstanding postdoctoral fellows or newly appointed assistant professors embarking on careers in pulmonary, critical care and sleep medicine. We seek to help them as they make the transition to independent, self-supporting, faculty members.
Eligibility & Requirements:
Internal Nomination Process:
No application deadline
The Michael J. Fox Foundation is sponsoring a $2 million prize to the first team to develop a viable selective alpha-synuclein PET tracer and agree to make that tracer available broadly.
The ability to image alpha-synuclein deposition
in the brain would be a game-changing achievement for the Parkinson's
disease (PD) field. The accumulation of aggregated alpha-synuclein is
a pathological hallmark of PD and a priority target for drug development
given its hypothesized contribution to neurodegeneration. In vivo imaging
of alpha-synuclein pathology could be useful as a biomarker of the presence
of disease and disease progression and as a pharmacodynamic tool for
drug development. With this prize, the Foundation seeks to attract research
teams and accelerate momentum to speed the development of such a tracer.
Contestants: Anyone is eligible for
the prize who agrees to all contest rules. Contestants may be MJFF funded
or not and can be from either academia or industry.
Criteria for winning: The winning contestant
must demonstrate that the radiotracer binds with relatively high selectivity
to alpha-synuclein according to pre-specified criteria and must demonstrate
proof-of-concept in human subjects, including people with Parkinson's
disease and/or another synucleinopathy. See below for more details on
Timeline: There is no deadline
for submissions. The $2 million award will be issued to the first
contestant who submits compelling evidence of a viable selective tracer
and agrees to its widespread use. If no award is given by mid-2018,
The Michael J. Fox Foundation will evaluate the state of the field and
utility of such a prize.